Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RadioCoBRIM: Vemurafenib + Cobimetinib after SRS for Melanoma Brain Metastases
NCT03430947Phase 2Terminated
- Sponsor
- Technische Universität Dresden
- Start
- Jul 2018
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib, cobimetinib in melanoma, sponsored by Technische Universität Dresden. Started Jul 2018; status: terminated.
02
Drugs
vemurafenibcobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03430947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430947.